Aerovate Therapeutics Inc
NASDAQ:AVTE

Watchlist Manager
Aerovate Therapeutics Inc Logo
Aerovate Therapeutics Inc
NASDAQ:AVTE
Watchlist
Price: 2.68 USD Market Closed
Market Cap: 77.4m USD
Have any thoughts about
Aerovate Therapeutics Inc?
Write Note

Aerovate Therapeutics Inc
Other Non-Cash Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aerovate Therapeutics Inc
Other Non-Cash Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Non-Cash Items CAGR 3Y CAGR 5Y CAGR 10Y
Aerovate Therapeutics Inc
NASDAQ:AVTE
Other Non-Cash Items
$8.8m
CAGR 3-Years
125%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Non-Cash Items
$7B
CAGR 3-Years
-10%
CAGR 5-Years
-6%
CAGR 10-Years
19%
Gilead Sciences Inc
NASDAQ:GILD
Other Non-Cash Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Other Non-Cash Items
-$419m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Non-Cash Items
$742.4m
CAGR 3-Years
37%
CAGR 5-Years
13%
CAGR 10-Years
4%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Non-Cash Items
$480.1m
CAGR 3-Years
24%
CAGR 5-Years
-6%
CAGR 10-Years
4%
No Stocks Found

Aerovate Therapeutics Inc
Glance View

Market Cap
77.4m USD
Industry
Biotechnology

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Boston, Massachusetts and currently employs 16 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The firm's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101's anti-proliferative mechanism is distinguished from vasodilatory therapies and is poised to make a meaningful difference in the lives of PAH patients. The firm has completed a Phase I trial in the United States of AV-101 in 82 healthy adults. In its Phase I trial, there were no adverse events associated with AV-101. The company anticipates initiating a double-blinded, placebo-controlled, randomized Phase II b/III trial of AV-101.

AVTE Intrinsic Value
4.24 USD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Aerovate Therapeutics Inc's Other Non-Cash Items?
Other Non-Cash Items
8.8m USD

Based on the financial report for Dec 31, 2023, Aerovate Therapeutics Inc's Other Non-Cash Items amounts to 8.8m USD.

What is Aerovate Therapeutics Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 3Y
125%

Over the last year, the Other Non-Cash Items growth was 94%. The average annual Other Non-Cash Items growth rates for Aerovate Therapeutics Inc have been 125% over the past three years .

Back to Top